scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 334, 1994, 1383–1389.
Sacks, F.M., Pfeffer, M.A., Moye, L.A., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335 (1996), 1001–1009.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. The long-term intervention with pravastatin in Ischaemic disease (LIPID) study group. N. Engl. J. Med., 339, 1998, 1349–1357.
West of Scotland coronary prevention study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet, 346, 1996, 1339–1342.
Downs, J.R., Clearfield, M., Weis, S., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. N. Engl. J. Med. 339 (1999), 1615–1622.
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., Bernini, F., New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84 (1999), 413–428.
Tedgui, A., Mallat, Z., Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 86 (2006), 515–581.
Parisi, V., Leosco, D., Ferro, G., Bevilacqua, A., Pagano, G., de Lucia, C., PerroneFilardi, P., Caruso, A., Rengo, G., Ferrara, N., The lipid theory in the pathogenesis of calcific aortic stenosis. Nutr. Metab. Cardiovasc. Dis. 25 (2015), 519–525.
Saito, S., Fujiwara, T., Matsunaga, T., Minagawa, K., Fukui, K., Fukuda, I., Osanai, T., Okumura, K., Increased adiponectin synthesis in the visceral adipose tissue in men with coronary artery disease treated with pravastatin: a role of the attenuation of oxidative stress. Atherosclerosis 199 (2008), 378–383.
Łabuzek, K., Bułdak, Ł., Duława-Bułdak, A., Bielecka, A., Krysiak, R., Madej, A., Okopień, B., Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia. Pharmacol. Rep. 63 (2011), 1124–1136.
Mazurek, T., Zhang, L., Zalewski, A., Mannion, J.D., Diehl, J.T., Arafat, H., Sarov-Blat, L., O'Brien, S., Keiper, E.A., Johnson, A.G., Martin, J., Goldstein, B.J., Shi, Y., Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 108 (2003), 2460–2466.
Baker, A.R., Silva, N.F., Quinn, D.W., Harte, A.L., Pagano, D., Bonser, R.S., Kumar, S., McTernan, P.G., Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc. Diabetol., 5, 2006, 1.
Parisi, V., Rengo, G., Pagano, G., D'Esposito, V., Passaretti, F., Caruso, A., Grimaldi, M.G., Lonobile, T., Baldascino, F., De Bellis, A., Formisano, P., Ferrara, N., Leosco, D., Epicardial adipose tissue has an increased thickness and is a source of inflammatory mediators in patients with calcific aortic stenosis. Int. J. Cardiol. 186 (2015), 167–169.
Baumgartner, H., Falk, V., Bax, J.J., De Bonis, M., Hamm, C., Holm, P.J., Iung, B., Lancellotti, P., Lansac, E., Muñoz, D.R., Rosenhek, R., Sjögren, J., Tornos Mas, P., Vahanian, A., Walther, T., Wendler, O., Windecker, S., Zamorano, J.L., ESC Scientific Document Group, 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur. Heart J. 38 (2017), 2739–2791.
Royston, P., Ambler, G., Sauerbrei, W., The use of fractional polynomials to model continuous risk variables in epidemiology. Int. J. Epidemiol. 28 (1999), 964–974.
Shorrocks, A.F., Decomposition procedures for distributional analysis: a unified framework based on the Shapley value. J. Econ. Inequal. 11 (2013), 99–126.
Royston, P., Sauerbrei, W., Multivariate Model Building. A Pragmatic Approach to Regression Analysis Based On Fractional Polynomials for Modeling Continuous Variables. 2008, Wiley, Chichester. UK, 183–186.
Kutner, M.H., Nachtsheim, C.J., Neter, J., Li, W., Applied Linear Statistical Models. 5th edition, 2005, McGraw Hill, Irwin, New York. NY, 409.
Suleiman, A.A., Analysis of multicollinearity in multiple regressions. Int. J. Adv. Technol. Eng. Sci. 3 (2015), 571–578.
Iacobellis, G., Ribaudo, M.C., Assael, F., Vecci, E., Tiberti, C., Zappaterreno, A., Di Mario, U., Leonetti, F., Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J. Clin. Endocrinol. Metab., 88, 2003, 5163e8.
Iacobellis, G., Leonetti, F., Epicardial adipose tissue and insulin resistance in obese subjects. J. Clin. Endocrinol. Metab. 90 (2005), 6300–6302.
Parisi, V., Rengo, G., Perrone-Filardi, P., Pagano, G., Femminella, G.D., Paolillo, S., Petraglia, L., Gambino, G., Caruso, A., Grimaldi, M.G., Baldascino, F., Nolano, M., Elia, A., Cannavo, A., De Bellis, A., Coscioni, E., Pellegrino, T., Cuocolo, A., Ferrara, N., Leosco, D., Increased epicardial adipose tissue volume correlates with cardiac sympathetic denervation in patients with heart failure. Circ. Res. 118 (2016), 1244–1253.
Park, J.H., Park, Y.S., Kim, Y.J., Lee, I.S., Kim, J.H., Lee, J.H., Choi, S.W., Jeong, J.O., Seong, I.W., Effects of statins on the epicardial fat thickness in patients with coronary artery stenosis underwent percutaneous coronary intervention: comparison of atorvastatin with simvastatin/ezetimibe. J. Cardiovasc. Ultrasound 18 (2010), 121–126.
Soucek, F., Covassin, N., Singh, P., Ruzek, L., Kara, T., Suleiman, M., Lerman, A., Koestler, C., Friedman, P.A., Lopez-Jimenez, F., Somers, V.K., Effects of atorvastatin (80 mg) therapy on quantity of epicardial adipose tissue in patients undergoing pulmonary vein isolation for atrial fibrillation. Am. J. Cardiol. 116 (2015), 1443–1446.
Alexopoulos, N., Melek, B.H., Arepalli, C.D., Hartlage, G.R., Chen, Z., Kim, S., Stillman, A.E., Raggi, P., Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (beyond endorsed lipid lowering with EBT scanning). J. Am. Coll. Cardiol. 61 (2013), 1956–1961.
Abe, M., Matsuda, M., Kobayashi, H., Miyata, Y., Nakayama, Y., Komuro, R., Fukuhara, A., Shimomura, I., Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages. Arterioscler. Thromb. Vasc. Biol. 28 (2008), 871–877.
Hartman, J., Frishman, W.H., Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol. Rev. 22 (2014), 147–151.
Gualtero, D.F., Viafara-Garcia, S.M., Morantes, S.J., Buitrago, D.M., Gonzalez, O.A., Lafaurie, G.I., Rosuvastatin inhibits interleukin (IL)-8 and IL-6 production in human coronary artery endothelial cells stimulated with Aggregatibacter actinomycetemcomitans serotype b. J. Periodontol. 88 (2017), 225–235.
Blyme, A., Asferg, C., Nielsen, O.W., Sehestedt, T., Kesäniemi, Y.A., Gohlke-Bärwolf, C., Boman, K., Willenheimer, R., Ray, S., Nienaber, C.A., Rossebø, A., Wachtell, K., Olsen, M.H., High sensitivity C reactive protein as a prognostic marker in patients with mild moderate aortic valve stenosis during lipid-lowering treatment: an SEAS substudy. Open Heart, 2, 2015, e000152.
Ridker, P.M., From C-Reactive Protein to Interleukin-6 to Interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ. Res. 118 (2016), 145–156.
Iacobellis, G., Willens, H.J., Echocardiographic epicardial fat: a review of research and clinical applications. J. Am. Soc. Echocardiogr. 22 (2009), 1311–1319.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
